Comunicati Stampa
Scienza e Tecnologia

Ad hoc: MorphoSys Updates its 2014 Financial Guidance

MorphoSys AG / Keyword(s): Pure forecast / Ad hoc: MorphoSys Updates its 2014 Financial Guidance . Ad hoc announcement according to § 15 WpHG. Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement. MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX OTC: MPSYY) today announced that it is adjusting its EBIT guidance for the current year...
New York, (informazione.it - comunicati stampa - scienza e tecnologia)

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX OTC: MPSYY) today announced that it is adjusting its EBIT guidance for the current year. MorphoSys now expects a negative EBIT in the range of EUR -5 million to EUR -8 million (from previously EUR -11 million to EUR -16 million). Reasons for the change are the now confirmed receipt of a milestone payment from Janssen, which directly affects the profit line, as well as a partial shift of proprietary development expenses to 2015. Revenues are now expected at the upper end of the previously communicated guidance range of EUR 58 million to EUR 63 million.

 

END OF AD HOC ANNOUNCEMENT


About MorphoSys:

MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare.

Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 80 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com .

 

 

HuCAL , HuCAL GOLD , HuCAL PLATINUM , CysDisplay , RapMAT , , Ylanthia and 100 billion high potentials are registered trademarks of MorphoSys AG.

Slonomics is a registered trademark of Sloning BioTechnology GmbH, a subsidiary of MorphoSys AG.

 

 


 

Dr. Claudia Gutjahr-Löser

Head of Corporate Communications & IR

 

Mario Brkulj

Associate Director Corporate Communications & IR

 

Alexandra Goller

Specialist Corporate Communications & IR

 

Jessica Rush

Specialist Corporate Communications & IR

 

investors@morphosys.com

 


Copyright GlobeNewswire

Attachment(s)
http://hugin.info/130295/R/1865031/654732.pdf

Regulatory News
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: %s via Globenewswire



Per maggiori informazioni
Ufficio Stampa
 Thomson Reuters (Leggi tutti i comunicati)
3 Times Square
10036 New York, NY